Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Sotzny, Franziska | - |
dc.contributor.author | Blanco, Julià | - |
dc.contributor.author | Capelli, Enrica | - |
dc.contributor.author | Castro-Marrero, Jesús | - |
dc.contributor.author | Steiner, Sophie | - |
dc.contributor.author | Murovska, Modra | - |
dc.contributor.author | Scheibenbogen, Carmen | - |
dc.contributor.other | on behalf of the European Network on ME/CFS (EUROMENE) | en_US |
dc.date.accessioned | 2021-01-14T07:54:31Z | - |
dc.date.available | 2021-01-14T07:54:31Z | - |
dc.date.issued | 2018 | - |
dc.identifier.uri | https://dspace.rsu.lv/jspui/handle/123456789/2901 | - |
dc.description.abstract | Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) is a frequent and severe chronic disease drastically impairing life quality. The underlying pathomechanismis incompletely understood yet but there is convincing evidence that in at least a subset of patients ME/CFS has an autoimmune etiology. In this review, we will discuss current autoimmune aspects forME/CFS. Immune dysregulation inME/CFS has been frequently described including changes in cytokine profiles and immunoglobulin levels, T- and B-cell phenotype and a decrease of natural killer cell cytotoxicity.Moreover, autoantibodies against various antigens including neurotransmitter receptors have been recently identified in ME/CFS individuals by several groups. Consistently, clinical trials from Norway have shown that B-cell depletion with rituximab results in clinical benefits in about half of ME/CFS patients. Furthermore, recent studies have provided evidence for severemetabolic disturbances presumably mediated by serum autoantibodies in ME/CFS. Therefore, further efforts are required to delineate the role of autoantibodies in the onset and pathomechanisms of ME/CFS in order to better understand and properly treat this disease. | en_US |
dc.language.iso | en | en_US |
dc.relation.ispartof | Autoimmunity Reviews Volume 17, Issue 6, June 2018, Pages 601-609; https://doi.org/10.1016/j.autrev.2018.01.009 | en_US |
dc.rights | info:eu-repo/semantics/openAccess | en_US |
dc.rights | Attribution 4.0 International | * |
dc.rights.uri | http://creativecommons.org/licenses/by/4.0/ | * |
dc.subject | Autoimmune | en_US |
dc.subject | Biomarker | en_US |
dc.subject | Myalgic Encephalomyeliti | en_US |
dc.subject | Chronic Fatigue Syndrome | en_US |
dc.subject | Autoantibodies | en_US |
dc.title | Myalgic Encephalomyelitis/Chronic Fatigue Syndrome – Evidence for an autoimmune disease | en_US |
dc.type | Article | en_US |
Appears in Collections: | Publications |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
Myalgic EncephalomyelitisChronic Fatigue Syndrome – Evidence for an autoimmune disease.pdf | 936.1 kB | Adobe PDF | View/Open |
This item is licensed under a Creative Commons License